Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693 | EVP, Head of International | August 12, 2026 | August 14, 2026 |
| Trevi Therapeutics, Inc.TRVI · Entity 4387 | See Remarks | February 13, 2020 | February 18, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RHYTHM PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 55,655 |
Ending reported balance
After 2026-08-12 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-08-12 · Exercise / conversion · Acquired 46,625 · Balance 112,655 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. Row 2 · 2026-08-12 · Sale · Disposed 2,300 · Balance 110,355 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2026-08-12 · Sale · Disposed 1,000 · Balance 109,355 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2026-08-12 · Sale · Disposed 3,605 · Balance 105,750 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 5 · 2026-08-12 · Sale · Disposed 14,568 · Balance 91,182 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 6 · 2026-08-12 · Sale · Disposed 18,208 · Balance 72,974 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 7 · 2026-08-12 · Sale · Disposed 17,319 · Balance 55,655 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.80 · Expires 2032-02-08 | Direct | 35,875 |
Reported balance
After 2026-08-12 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-08-12 · Exercise / conversion · Disposed 46,625 · Balance 35,875 F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F8: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026.
F2: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.
Trevi Therapeutics, Inc.
Report date February 13, 2020 · Filed February 18, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2030-02-12 | Direct | 70,000 |
Reported balance
After 2020-02-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-13 · Grant · Acquired 70,000 · Balance 70,000 F1: This option was granted on February 13, 2020. The 70,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on February 13, 2020. The 70,000 shares of common stock underlying the option are scheduled to vest as to 25% of the shares on February 13, 2021 and as to the remaining 75% of the shares in equal monthly installments thereafter through February 13, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 46,625 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · derivative · entry 8 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,875 Underlying: Common Stock · 46,625 shares Expires 2032-02-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F8 · derivative.exercise_date: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 17,319 | $117.47 | $2,034,438.68 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 7 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,655 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.01 to $117.60 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 18,208 | $116.49 | $2,121,124.57 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 6 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,974 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F6 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $116.01 to $117.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 14,568 | $115.43 | $1,681,540.54 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 5 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,182 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F5 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $115.01 to $116.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 3,605 | $114.70 | $413,477.28 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,750 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F4 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $114.01 to $115.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,000 | $112.86 | $112,856.00 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,355 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $112.84 to $112.92 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 2,300 | $111.80 | $257,138.16 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 110,355 F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $111.58 to $112.30 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2026 Filed Aug 14, 2026 23:01 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 46,625 | $6.80 | $317,050.00 |
DisclosureSEC source: 0001649904-26-000007 · form4.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 13, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-039687 · tm2611099-1_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 1, 2026, April 1, 2027 and April 1, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 1, 2026, April 1, 2027 and April 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-039687 · tm2611099-1_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,375 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 1, 2026 and April 1, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 1, 2026 and April 1, 2027. The restricted stock units have no expiration date. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 21:36 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 12,875 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-039687 · tm2611099-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,030 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:22 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $94.94 | $0.00 |
DisclosureSEC source: 0001104659-26-023659 · tm268041-1_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2036-03-01 F1 · derivative.exercise_date: The stock options were granted on March 2, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-017082 · tm266636-1_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 10,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 1, 2027, February 1, 2028 and February 1, 2029. The restricted stock units have no expiration date. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 21:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-017082 · tm266636-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 11, 2026 Filed Feb 13, 2026 22:50 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 23,350 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-015400 · tm266366-5_4seq1.xml · derivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,350 Underlying: Common Stock · 23,350 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of March 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of March 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-009772 · tm264963-9_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 1, 2026, February 1, 2027 and February 1, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 01, 2026 Filed Feb 3, 2026 21:38 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-009772 · tm264963-9_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| April 29, 2025 Filed May 1, 2025 20:52 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 6,745 | $65.08 | $438,946.39 |
DisclosureSEC source: 0001104659-25-043555 · tm2513769-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,655 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $65.00 to $65.22 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035516 · tm2512416-1_4seq1.xml · derivative · entry 5 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 15, 2026, April 15, 2027 and April 15, 2028. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 15, 2026, April 15, 2027 and April 15, 2028. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 8,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035516 · tm2512416-1_4seq1.xml · derivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,905 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units have vested in full on April 15, 2025. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units have vested in full on April 15, 2025. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2025 Filed Apr 16, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 11,405 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-035516 · tm2512416-1_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-035516 · tm2512416-1_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,750 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. Read SEC document |
| April 14, 2025 Filed Apr 16, 2025 20:30 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-035516 · tm2512416-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,995 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 9,312 | $61.54 | $573,062.34 |
DisclosureSEC source: 0001104659-25-033820 · tm2512047-1_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,620 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $61.04 to $62.00 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 08, 2025 Filed Apr 10, 2025 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 8,438 | $60.37 | $509,434.97 |
DisclosureSEC source: 0001104659-25-033820 · tm2512047-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 31,932 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $60.00 to $60.91 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 01:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionStock Options (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $22.28 | $0.00 |
DisclosureSEC source: 0001104659-25-025236 · tm259548-1_4seq1.xml · derivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 75,000 shares Expires 2030-10-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The options are fully vested. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 01:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 55,803 | $51.72 | $2,886,226.03 |
DisclosureSEC source: 0001104659-25-025236 · tm259548-1_4seq1.xml · nonDerivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,370 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F3 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $51.31 to $52.04 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 01:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 19,197 | $50.79 | $975,046.35 |
DisclosureSEC source: 0001104659-25-025236 · tm259548-1_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,173 F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 13, 2024. F2 · price: The price reported in Column 4 is a weighted average price. The securities were sold in multiple transactions at prices ranging from $50.31 to $51.26 per common stock. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 14, 2025 Filed Mar 19, 2025 01:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 75,000 | $22.28 | $1,671,000.00 |
DisclosureSEC source: 0001104659-25-025236 · tm259548-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 5,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015321 · tm257103-5_4seq1.xml · derivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,500 Underlying: Common Stock · 5,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 5,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-25-015321 · tm257103-5_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,370 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $56.69 | $0.00 |
DisclosureSEC source: 0001104659-25-015321 · tm257103-5_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2035-02-13 F3 · derivative.exercise_date: The stock options were granted on February 14, 2025. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 14, 2025 Filed Feb 20, 2025 02:47 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-015321 · tm257103-5_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 14, 2026, February 14, 2027, February 14, 2028 and February 14, 2029. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · derivative · entry 6 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F8 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 15, 2026, April 15, 2027 and April 15, 2028. The restricted stock units have no expiration date. F8 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 15, 2025, April 15, 2026, April 15, 2027 and April 15, 2028. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 8,905 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · derivative · entry 5 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,905 Underlying: Common Stock · 8,905 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F7 · derivative.exercise_date: The restricted stock units vest in full on April 15, 2025. The restricted stock units have no expiration date. F7 · derivative.expiration_date: The restricted stock units vest in full on April 15, 2025. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Disposition to issuerRestricted Stock Units · Derivative | 6,874 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · derivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,874 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F5 · kind: The restricted stock units were rescinded and cancelled by mutual agreement of the reporting person and Issuer. The reporting person received French-qualified restricted stock units on April 15, 2024 as consideration for the recission and cancellation of the unvested portion of the restricted stock previously received on February 9, 2022. F6 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F6 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| April 15, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Disposition to issuerRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,031 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · kind: The restricted stock units were rescinded and cancelled by mutual agreement of the reporting person and Issuer. The reporting person received French-qualified restricted stock units on April 15, 2024 as consideration for the recission and cancellation of the unvested portion of the restricted stock previously received on February 11, 2021. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| April 14, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 10,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,125 Underlying: Common Stock · 10,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. Read SEC document |
| April 14, 2024 Filed Apr 17, 2024 00:11 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 10,375 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-047957 · tm2411921-1_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,870 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| March 19, 2024 Filed Mar 20, 2024 00:53 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 16,000 | $39.22 | $627,520.00 |
DisclosureSEC source: 0001104659-24-036315 · tm249308-3_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,495 F1 · kind: The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $39.10 to $39.22. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantStock Option (Right to Buy) · Derivative | 67,000 | $0.00 Strike: $49.23 | $0.00 |
DisclosureSEC source: 0001104659-24-026160 · tm246920d6_4seq1.xml · derivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2034-02-15 F4 · derivative.exercise_date: The stock options were granted on February 16, 2024. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026160 · tm246920d6_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of February 16, 2025, February 16, 2026, February 16, 2027 and February 16, 2028. The restricted stock units have no expiration date. Read SEC document |
| February 16, 2024 Filed Feb 22, 2024 00:02 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantCommon Stock | 33,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-026160 · tm246920d6_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,495 F1 · shares: The Issuer previously granted the Reporting Person an award of restricted stock units that vest based on the Issuer's satisfaction of certain performance objectives. On February 16, 2024, the Board determined that the performance condition had been satisfied. Read SEC document |
| February 13, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 957 | $49.84 | $47,696.88 |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · nonDerivative · entry 4 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,745 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 12, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | SaleCommon Stock | 1,594 | $51.38 | $81,899.72 |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · nonDerivative · entry 3 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,702 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 2,031 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · derivative · entry 6 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,031 Underlying: Common Stock · 2,031 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 11, 2022, February 11, 2023, February 11, 2024 and February 11, 2025. The restricted stock units have no expiration date. Read SEC document |
| February 11, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 2,031 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · nonDerivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,296 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionRestricted Stock Units · Derivative | 3,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · derivative · entry 5 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,874 Underlying: Common Stock · 3,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F3 · derivative.exercise_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. F3 · derivative.expiration_date: The restricted stock units vest or have vested as to 25% of the total shares on each of February 9, 2023, February 9, 2024, February 9, 2025 and February 9, 2026. The restricted stock units have no expiration date. Read SEC document |
| February 09, 2024 Filed Feb 14, 2024 01:49 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | Exercise / conversionCommon Stock | 3,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-022539 · tm246165-4_4seq1.xml · nonDerivative · entry 1 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,265 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| April 14, 2023 Filed Apr 18, 2023 21:16 UTC | RHYTHM PHARMACEUTICALS, INC. RYTM · Entity 3693 | GrantRestricted Stock Units · Derivative | 41,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-046815 · tm2313124-1_4seq1.xml · derivative · entry 2 Mazabraud Yann · CIK 0001774702 · EVP, Head of International 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,500 Underlying: Common Stock · 41,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vest as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. F4 · derivative.expiration_date: The restricted stock units vest as to 25% of the total shares on each of April 14, 2024, April 14, 2025, April 14, 2026 and April 14, 2027. The restricted stock units have no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.